CIP2A and hepatocellular carcinoma: In our previous studies, we demonstrated that bortezomib, a proteasome inhibitor, induced apoptosis via proteasome-independent inhibition of CIP2A in triple-negative breast cancer cells [25], hepatocellular carcinoma cells [44], leukemia cells [24] and head and neck cancer cells [41].